Physician profile
John Dermigny
NPI 1316987688
$3,411.84
in general payments reported to CMS, 2019-2025
30 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $66.88 · 2021: $358 · 2022: $522 · 2023: $700 · 2024: $736 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $567.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $380.45 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $346.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $342.08 | 2021-2024 | Ubrelvy, Linzess, Viberzi |
| Pfizer INC. | $303.00 | 2019-2025 | |
| Abbott Laboratories | $165.96 | 2021-2025 | Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $150.11 | 2022-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $143.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $133.13 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.54 | 2023-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $115.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.59 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| E.R. Squibb & Sons, L.L.C. | $74.58 | 2022-2025 | Eliquis |
| Axsome Therapeutics, INC. | $68.20 | 2023-2025 | Auvelity |
| Sanofi Pasteur INC. | $54.83 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.42 | 2022-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Indivior INC. | $41.99 | 2024 | Sublocade |
| Biogen, INC. | $36.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.78 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $23.94 | 2025 | Keveyis |
| Baxter Healthcare | $23.52 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $20.59 | 2025 | |
| Phathom Pharmaceuticals, INC. | $19.68 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.85 | 2023 | |
| Exact Sciences Corporation | $17.72 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $17.68 | 2025 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2022 | |
| Amarin Pharma, INC. | $15.71 | 2022 | |
| Esperion Therapeutics, INC. | $14.97 | 2021 | |
| Currax Pharmaceuticals LLC | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dermigny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.